Logo

WGS

GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp. • NASDAQ
$166.95 ▲ 0.81% (+1.34)
Market Cap $4.83 B
52w High $170.75
52w Low $55.17
Dividend Yield 0%
P/E 1391.25
Volume 158.70K
Outstanding Shares 28.90M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $116.743M ▲ $87.778M ▲ $-7.635M ▼ -6.54% ▼ $-0.27 ▼ $-352K ▼
Q2-2025 $102.692M ▲ $61.942M ▼ $10.809M ▲ 10.526% ▲ $0.38 ▲ $17.571M ▲
Q1-2025 $87.115M ▼ $63.027M ▲ $-6.529M ▼ -7.495% ▼ $-0.23 ▼ $236K ▼
Q4-2024 $95.64M ▲ $57.399M ▲ $5.438M ▲ 5.686% ▲ $0.2 ▲ $14.364M ▲
Q3-2024 $76.874M $55.609M $-8.312M -10.812% $-0.31 $-1.851M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $155.079M ▲ $493.902M ▲ $201.644M ▲ $292.258M ▲
Q2-2025 $134.558M ▼ $463.863M ▲ $186.73M ▼ $277.133M ▲
Q1-2025 $159.16M ▲ $446.43M ▲ $189.025M ▲ $257.405M ▲
Q4-2024 $141.185M ▲ $419.38M ▲ $174.133M ▼ $245.247M ▲
Q3-2024 $116.46M $408.84M $204.339M $204.501M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-7.635M ▼ $15.767M ▲ $-4.687M ▲ $10.768M ▲ $21.848M ▲ $9.595M ▲
Q2-2025 $10.809M ▲ $10.42M ▲ $-36.35M ▼ $346K ▼ $-25.584M ▼ $8.051M ▲
Q1-2025 $-6.529M ▼ $10.182M ▲ $-9.408M ▼ $13.718M ▼ $14.492M ▼ $4.053M ▲
Q4-2024 $5.438M ▲ $-3.183M ▲ $-519K ▲ $31.023M ▲ $27.321M ▲ $-6.233M ▼
Q3-2024 $-8.312M $-4.395M $-7.755M $13.968M $1.818M $-5.041M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Diagnostic Test
Diagnostic Test
 $160.00M ▲$90.00M ▼$100.00M ▲$110.00M ▲
Diagnostic Test Institutional Customers
Diagnostic Test Institutional Customers
 $30.00M ▲$20.00M ▼$20.00M ▲$20.00M ▲
Diagnostic Test Self Pay
Diagnostic Test Self Pay
 $0 ▲$0 ▲$0 ▲$0 ▲
Diagnostic Test Third Party Insurance
Diagnostic Test Third Party Insurance
 $120.00M ▲$70.00M ▼$80.00M ▲$100.00M ▲
Product and Service Other
Product and Service Other
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has been climbing gradually over the past several years, showing that demand for GeneDx’s services is growing. The quality of that revenue has also improved: the company has moved from losing money on each dollar of sales to generating a healthier gross profit. However, the business is still not profitable overall. Operating losses and net losses remain meaningful, even though they have narrowed recently. In simple terms, the core commercial engine is gaining traction, but the company is still spending more on operations, overhead, and development than it brings in, and it has yet to prove consistent, sustainable profitability.

Balance Sheet

Balance Sheet The balance sheet shows a company that has repaired earlier weaknesses but still runs with a relatively thin cushion. Total assets are modest and have stayed in roughly the same range in recent years. Equity has swung from negative several years ago to solidly positive, which is a structural improvement and suggests past recapitalization and cleanup of the capital structure. Cash levels, however, have come down from prior peaks, meaning there is less immediate liquidity than before. Debt exists but is not overly large relative to the size of the business. Overall, GeneDx now has a healthier foundation than it did at the start of the period, but it does not have an abundance of balance sheet slack if conditions worsen or investment needs rise.

Cash Flow

Cash Flow GeneDx continues to burn cash in its day‑to‑day operations. Operating cash flow has been negative throughout, although the cash burn has eased somewhat over time. Capital spending is modest, so most of the outflow comes from funding ongoing losses rather than heavy investment in physical assets. Free cash flow remains negative, which means the company still relies on its cash reserves or external financing to fund its strategy. Progress is visible in the direction of improving cash usage, but the business is not yet self‑funding, and its ability to sustain investment will depend on careful cost management and access to additional capital if needed.

Competitive Edge

Competitive Edge Competitively, GeneDx occupies a focused and differentiated niche in genomic diagnostics, especially for rare and complex diseases and critical care settings like neonatal intensive care units. Its long history in exome and genome sequencing, combined with deep relationships with geneticists and pediatric specialists, gives it credibility and referral flow that are not easy to replicate. The centerpiece of its moat is a large, proprietary database of genomic and clinical information, which improves the accuracy and speed of its diagnoses and strengthens its artificial intelligence tools over time. Integration with major electronic health record systems and recognition from regulators further support its positioning. On the risk side, it operates in a field where large, well‑funded competitors, changing reimbursement policies, rapid technology shifts, and regulatory scrutiny can all pressure margins and market share. Its edge is strong but must be continually reinforced.

Innovation and R&D

Innovation and R&D Innovation is a clear strength. GeneDx has been early in whole exome and whole genome sequencing, and it has pushed into ultra‑rapid genome testing for critically ill newborns, where hours and days matter. The company embeds artificial intelligence and machine learning into its interpretation process, using tools trained on its own extensive database to prioritize genes and variants more effectively. It is also investing in emerging areas like genomic newborn screening, which could shift care from reactive to preventative if adoption broadens. Planned integration of Fabric Genomics supports a more decentralized testing model, combining local labs with centralized analytics. Collaborations that extend its technology into broader disease risk assessment highlight potential new applications. The flip side is that this level of R&D intensity is expensive, outcomes are uncertain, and timelines can be long, so the company must balance scientific ambition with financial discipline.

Summary

GeneDx is evolving from an early‑stage genomic diagnostics player into a more mature, data‑driven platform company. Commercial momentum is improving and gross profitability has strengthened, but the business still operates with ongoing losses and cash burn. The balance sheet is healthier than in the past, yet not overly robust, leaving limited room for prolonged setbacks without new funding. Strategically, GeneDx’s advantages lie in its rare disease focus, massive proprietary dataset, advanced sequencing capabilities, and AI‑enabled interpretation tools, all reinforced by strong clinical relationships and growing integration into hospital workflows. Innovation efforts around rapid genome testing, newborn screening, and decentralized testing create meaningful long‑term opportunity but also require sustained investment and come with execution and regulatory risk. Overall, this is a company with a strong technological and data foundation that is still working to fully translate its scientific edge into durable, self‑sustaining financial performance.

NEWS

November 6, 2025 · 8:00 AM UTC

GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting

Read more

October 28, 2025 · 6:30 AM UTC

GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

Read more

October 27, 2025 · 8:00 AM UTC

GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims

Read more

October 24, 2025 · 9:40 AM UTC

Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights

Read more

October 22, 2025 · 8:00 AM UTC

GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025

Read more